PFM Health Sciences, LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001442756
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2025 · 69 positions · Total reported value $1.23B · Top-10 concentration 51.9% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 75.8% · 24 new · 28 cut · 39 exited
Active Share (vs S&P 500): 96.6% · vs QQQ: 99.7% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -4.9% · vs SPY -7.0% · Prev Value $1.14B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): +2.3% · vs SPY +0.2% · Latest Value $978.49M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q3 2025 13F filing, PFM Health Sciences, LP disclosed 69 equity positions with a combined reported value of $1.23B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 51.9% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2025 were LLY ($171.78M), THC ($93.73M), XBI ($71.88M). By sector, the heaviest allocations are Health Care 82.6%, Consumer Staples 2.1%. Versus the prior quarter, allocation shifted toward Other (+2.8pp), Technology (+1.0pp) and away from Consumer Staples (-0.8pp), Industrials (-3.4pp).
Versus the prior quarter, PFM Health Sciences, LP opened 24 new positions, trimmed 28 and fully exited 39, a turnover rate of 75.8% of positions. The portfolio's overlap with the prior quarter was 53% of names.
The largest new positions opened in Q3 2025 were XBI ($71.88M), UHS ($23.77M), CNC ($20.49M).
Of the 39 positions fully exited versus the prior quarter, the largest were DHR ($31.89M), MOH ($25.54M), ALNY ($23.55M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2025)
Fully Exited (vs previous quarter)
- DHR DANAHER CORP DEL · prev qtr: $31.89M · history
- MOH MOLINA HEALTHCARE INC · prev qtr: $25.54M
- ALNY ALNYLAM PHARMACEUTICALS INC · prev qtr: $23.55M
- MASI MASIMO CORP · prev qtr: $15.89M
- HOLX HOLOGIC IN · prev qtr: $13.81M
- UNH UNITEDHEALTH GROUP INC · prev qtr: $10.80M · history
- BMRN BIOMARIN PHARMACEUTICAL INC · prev qtr: $9.80M
- ABBV ABBVIE INC · prev qtr: $7.57M
Insider Transactions (Form 4)
Latest PFM Health Sciences, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
PFM Health Sciences, LP is an SEC-registered 13F filer based in San Francisco, CA, United States. As of Q2 2026 it reported 96 US equity positions with a combined value of $1.14B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: SAN FRANCISCO, CA, United States
- SEC registration: 801-69012 (status: Approved), registered 2008-04-10
- Regulatory AUM (Form ADV): $1.27B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 4 private funds, of which 2 hedge funds
- Website: pfmhealthsciences.com
Portfolio Structure
- 96 positions · $1.14B reported value (Q2 2026)
- Top 10 holdings = 34.6% of reported value
- Largest position: ASND (ASCENDIS PHARMA A/S) at 5.4%
- Average position size: $11.89M
Sector Tilt
- Health Care 92.9%
- Industrials 5.1%
- Consumer Staples 1.2%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 32 new, 24 added, 40 reduced, 14 exited
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
225.14K | $171.78M | 13.95% | Reduce | |
| 2 |
|
461.65K | $93.73M | 7.61% | Reduce | |
| 3 |
|
717.40K | $71.88M | 5.84% | New | |
| 4 |
|
530.33K | $64.41M | 5.23% | Add | |
| 5 |
|
72.31K | $55.86M | 4.54% | Hold | |
| 6 |
|
195.09K | $49.42M | 4.01% | Add | |
| 7 |
|
95.65K | $40.10M | 3.26% | Add | |
| 8 |
|
77.40K | $34.62M | 2.81% | Reduce | |
| 9 |
|
381.32K | $29.66M | 2.41% | Reduce | |
| 10 |
|
65.77K | $28.03M | 2.28% | Reduce | |
| 11 |
|
346.68K | $26.14M | 2.12% | Reduce | |
| 12 |
|
80.49K | $25.16M | 2.04% | Add | |
| 13 |
|
1.73M | $24.43M | 1.98% | Add | |
| 14 |
|
116.26K | $23.77M | 1.93% | New | |
| 15 |
|
133.68K | $23.39M | 1.90% | Add | |
| 16 |
|
574.36K | $20.49M | 1.67% | New | |
| 17 |
|
236.47K | $19.85M | 1.61% | New | |
| 18 |
|
60.78K | $19.64M | 1.59% | New | |
| 19 |
|
115.60K | $18.61M | 1.51% | Add | |
| 20 |
|
1.18M | $17.31M | 1.41% | New | |
| 21 |
|
2.21M | $17.05M | 1.39% | Add | |
| 22 |
|
327.17K | $16.99M | 1.38% | Reduce | |
| 23 |
|
243.40K | $16.45M | 1.34% | Reduce | |
| 24 |
|
666.20K | $16.16M | 1.31% | Add | |
| 25 |
|
11.52M | $15.70M | 1.28% | Reduce | |
| 26 |
|
820.64K | $15.53M | 1.26% | Add | |
| 27 |
|
331.07K | $15.46M | 1.26% | New | |
| 28 |
|
513.68K | $14.93M | 1.21% | New | |
| 29 |
|
21.21K | $14.13M | 1.15% | Add | |
| 30 |
|
56.70K | $13.72M | 1.11% | New | |
| 31 |
|
561.53K | $13.54M | 1.10% | Reduce | |
| 32 |
|
41.50K | $12.36M | 1.00% | New | |
| 33 |
|
130.74K | $12.31M | 1.00% | Reduce | |
| 34 |
|
248.08K | $11.78M | 0.96% | Reduce | |
| 35 |
|
19.89K | $11.18M | 0.91% | New | |
| 36 |
|
65.00K | $11.18M | 0.91% | Reduce | |
| 37 |
|
1.66M | $9.53M | 0.77% | Reduce | |
| 38 |
|
30.75K | $9.22M | 0.75% | Reduce | |
| 39 |
|
80.42K | $8.58M | 0.70% | Hold | |
| 40 |
|
239.64K | $8.07M | 0.66% | Reduce | |
| 41 |
|
57.25K | $8.04M | 0.65% | Add | |
| 42 |
|
356.82K | $7.21M | 0.58% | Reduce | |
| 43 |
|
360.46K | $6.79M | 0.55% | Reduce | |
| 44 |
|
157.87K | $6.36M | 0.52% | New | |
| 45 |
|
436.16K | $5.93M | 0.48% | Reduce | |
| 46 |
|
74.36K | $5.10M | 0.41% | New | |
| 47 |
|
48.16K | $4.86M | 0.40% | New | |
| 48 |
|
183.54K | $4.82M | 0.39% | Add | |
| 49 |
|
18.36K | $4.82M | 0.39% | New | |
| 50 |
|
61.80K | $4.74M | 0.39% | New | |
FAQ
What did PFM Health Sciences, LP buy in 2025-Q3?
In its 2025-Q3 13F filing, PFM Health Sciences, LP reported 69 equity positions worth $1.23B in aggregate; its largest disclosed positions were LLY ($171.78M), THC ($93.73M), XBI ($71.88M).
How large is PFM Health Sciences, LP's portfolio?
PFM Health Sciences, LP reported $1.23B of long equity holdings across 69 positions as of 2025-Q3. Top-10 holdings account for 51.9% of reported value.
What is PFM Health Sciences, LP's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.